Simon Peter Cooper - 21 Jan 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Medical Officer
Issuer ticker: KROS
Reported as of: 21 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jan 2022, 15:12:21 UTC
Prior SEC filing: 11 Aug 2021
Next SEC filing: 17 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Simon Peter Cooper filed Form 4 for Keros Therapeutics, Inc. (KROS) on 25 Jan 2022.

Key facts

This page summarizes Simon Peter Cooper's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Jan 2022, 15:12.

Change

Previous filing in this sequence was filed on 11 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 21 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $46.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.